{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:10:03Z","timestamp":1794309003264,"version":"4.9.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma is the most frequent monoclonal gammopathy to involve the kidney; however, a growing number of kidney diseases associated with other monoclonal gammopathies are being recognized. Although many histopathologic patterns exist, they are all distinguished by the monoclonal immunoglobulin (or component) deposits. The hematologic disorder in these patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS) than with multiple myeloma. Unfortunately, due to the limitations of the current diagnostic schema, they are frequently diagnosed as MGUS. Because treatment is not recommended for MGUS, appropriate therapy is commonly withheld. In addition to end-stage renal disease, the persistence of the monoclonal gammopathy is associated with high rates of recurrence after kidney transplantation. Preservation and restoration of kidney function are possible with successful treatment targeting the responsible clone. Achievement of hematologic complete response has been shown to prevent recurrence after kidney transplantation. There is a need for a term that properly conveys the pathologic nature of these diseases. We think the term monoclonal gammopathy of renal significance is most helpful to indicate a causal relationship between the monoclonal gammopathy and the renal damage and because the significance of the monoclonal gammopathy is no longer undetermined.<\/jats:p>","DOI":"10.1182\/blood-2012-07-445304","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T06:39:17Z","timestamp":1349851157000},"page":"4292-4295","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":503,"title":["Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant"],"prefix":"10.1182","volume":"120","author":[{"given":"Nelson","family":"Leung","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN;"},{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, University Hospital Poitiers, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin A.","family":"Hutchison","sequence":"additional","affiliation":[{"name":"Renal Institute of Birmingham, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih H.","family":"Nasr","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cockwell","sequence":"additional","affiliation":[{"name":"Renal Institute of Birmingham, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Fermand","sequence":"additional","affiliation":[{"name":"Univerisity Hospital St Louis, Paris, Ile De France, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Hematology, Vancouver General Hospital, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2019111705251476200_B1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111705251476200_B2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"2019111705251476200_B3","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111705251476200_B4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111705251476200_B5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111705251476200_B6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"issue":"33","key":"2019111705251476200_B7","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111705251476200_B8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.","volume":"158","author":"Blade","year":"1998","journal-title":"Arch Intern Med"},{"issue":"1","key":"2019111705251476200_B9","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases.","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"6","key":"2019111705251476200_B10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","article-title":"Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.","volume":"42","author":"Pozzi","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2019111705251476200_B11","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits.","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2019111705251476200_B12","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones.","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"2019111705251476200_B13","first-page":"74","article-title":"A case of bilateral renal arterial thrombosis associated with cryocrystalglobulinaemia.","volume":"3","author":"Leung","year":"2010","journal-title":"Nephrol Dial Transplant Plus"},{"issue":"7","key":"2019111705251476200_B14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","article-title":"Renal monoclonal immunoglobulin deposition disease: the disease spectrum.","volume":"12","author":"Lin","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2019111705251476200_B15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10157-005-0361-z","article-title":"Fibrillary glomerulonephritis associated with monoclonal gammopathy of undetermined significance showing lambda-type Bence Jones protein.","volume":"9","author":"Nagao","year":"2005","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"2019111705251476200_B16","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"2019111705251476200_B17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJM199106273242603","article-title":"Nephrotoxic potential of Bence Jones proteins.","volume":"324","author":"Solomon","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111705251476200_B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2010.05.001","article-title":"Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience.","volume":"79","author":"Stratta","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2019111705251476200_B19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma.","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111705251476200_B20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(12)80314-3","article-title":"Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease.","volume":"20","author":"Heilman","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2019111705251476200_B21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2005.10.023","article-title":"A proliferative glomerulonephritis secondary to a monoclonal IgA.","volume":"47","author":"Soares","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2019111705251476200_B22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2215\/CJN.05750710","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft.","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2019111705251476200_B23","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","article-title":"Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features.","volume":"63","author":"Rosenstock","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"2019111705251476200_B24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1046\/j.1523-1755.2002.00628.x","article-title":"Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features.","volume":"62","author":"Bridoux","year":"2002","journal-title":"Kidney Int"},{"issue":"3","key":"2019111705251476200_B25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0272-6386(12)70138-5","article-title":"Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy.","volume":"22","author":"Fogo","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2019111705251476200_B26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00125480-200401000-00005","article-title":"Dysproteinemia and the kidney.","volume":"11","author":"Markowitz","year":"2004","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"2019111705251476200_B27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000180197","article-title":"Waldenstrom's macroglobulinemia, mesangio-capillary glomerulonephritis, angiitis and myositis.","volume":"10","author":"Lin","year":"1973","journal-title":"Nephron"},{"issue":"1","key":"2019111705251476200_B28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0272-6386(03)00412-8","article-title":"Monoclonal gammopathy: significance and possible causality in renal disease.","volume":"42","author":"Paueksakon","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2019111705251476200_B29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis: a new look at an old entity.","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111705251476200_B30","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2215\/CJN.06760909","article-title":"Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.","volume":"5","author":"Sethi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2019111705251476200_B31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2010.1","article-title":"Recurrent membranoproliferative glomerulonephritis after kidney transplantation.","volume":"77","author":"Lorenz","year":"2010","journal-title":"Kidney Int"},{"issue":"1","key":"2019111705251476200_B32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease.","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2019111705251476200_B33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000046254","article-title":"Recurrence of light chain nephropathy in a renal allograft: a case report and review of the literature.","volume":"21","author":"Short","year":"2001","journal-title":"Am J Nephrol"},{"issue":"4","key":"2019111705251476200_B34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/ki.2008.577","article-title":"Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits.","volume":"75","author":"Czarnecki","year":"2009","journal-title":"Kidney Int"},{"issue":"24","key":"2019111705251476200_B35","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111705251476200_B36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies.","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"issue":"5","key":"2019111705251476200_B37","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.","volume":"51","author":"Katzmann","year":"2005","journal-title":"Clin Chem"},{"issue":"5","key":"2019111705251476200_B38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis: a report to the Medical Research Council's working party on leukaemia in adults.","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br J Cancer"},{"issue":"8","key":"2019111705251476200_B39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma.","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2019111705251476200_B40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V52.4.818.bloodjournal524818","article-title":"Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.","volume":"52","author":"Kyle","year":"1978","journal-title":"Blood"},{"issue":"6","key":"2019111705251476200_B41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/0002-9343(85)90521-2","article-title":"Primary systemic amyloidosis: comparison of melphalan\/prednisone versus colchicine.","volume":"79","author":"Kyle","year":"1985","journal-title":"Am J Med"},{"issue":"3","key":"2019111705251476200_B42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"issue":"12","key":"2019111705251476200_B43","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111705251476200_B44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019111705251476200_B45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111705251476200_B46","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111705251476200_B47","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111705251476200_B48","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111705251476200_B49","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase I\/II study of lenalidomide with low dose oral cyclophosphamide and low dose dexamethasone(RdC) in AL amyloidosis.","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111705251476200_B50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.ajkd.2005.05.010","article-title":"Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.","volume":"46","author":"Leung","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2019111705251476200_B51","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2215\/CJN.02450706","article-title":"Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.","volume":"2","author":"Leung","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2019111705251476200_B52","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3324\/haematol.13548","article-title":"Treatment of light chain deposition disease with bortezomib and dexamethasone.","volume":"94","author":"Kastritis","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2019111705251476200_B53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bmt.2008.179","article-title":"High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.","volume":"42","author":"Hassoun","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111705251476200_B54","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease.","volume":"23","author":"Lorenz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2019111705251476200_B55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705447","article-title":"Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation.","volume":"38","author":"Weichman","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111705251476200_B56","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"2019111705251476200_B57","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111705251476200_B58","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111705251476200_B59","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/22\/4292\/1360540\/zh804812004292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/22\/4292\/1360540\/zh804812004292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T04:06:08Z","timestamp":1643515568000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/22\/4292\/73069\/Monoclonal-gammopathy-of-renal-significance-when"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,22]]},"references-count":59,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2012,11,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-07-445304","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,22]]}}}